[go: up one dir, main page]

DE60140285D1 - Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts - Google Patents

Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts

Info

Publication number
DE60140285D1
DE60140285D1 DE60140285T DE60140285T DE60140285D1 DE 60140285 D1 DE60140285 D1 DE 60140285D1 DE 60140285 T DE60140285 T DE 60140285T DE 60140285 T DE60140285 T DE 60140285T DE 60140285 D1 DE60140285 D1 DE 60140285D1
Authority
DE
Germany
Prior art keywords
growth hormone
mobility
promote
digestive tract
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60140285T
Other languages
English (en)
Inventor
John Hakkinen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Raqualia Pharma Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Application granted granted Critical
Publication of DE60140285D1 publication Critical patent/DE60140285D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60140285T 2000-05-31 2001-05-16 Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts Expired - Lifetime DE60140285D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20823400P 2000-05-31 2000-05-31

Publications (1)

Publication Number Publication Date
DE60140285D1 true DE60140285D1 (de) 2009-12-10

Family

ID=22773794

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60140285T Expired - Lifetime DE60140285D1 (de) 2000-05-31 2001-05-16 Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts

Country Status (14)

Country Link
US (2) US6548501B2 (de)
EP (1) EP1159964B1 (de)
JP (4) JP3842987B2 (de)
KR (1) KR20010109139A (de)
AT (1) ATE446758T1 (de)
AU (1) AU4811401A (de)
CA (1) CA2349142C (de)
DE (1) DE60140285D1 (de)
ES (1) ES2333097T3 (de)
HU (1) HUP0102272A3 (de)
IL (1) IL143388A0 (de)
MY (1) MY134190A (de)
NZ (1) NZ512072A (de)
ZA (1) ZA200104396B (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821285B2 (en) * 1999-06-22 2004-11-23 Ndo Surgical, Inc. Tissue reconfiguration
US6494888B1 (en) * 1999-06-22 2002-12-17 Ndo Surgical, Inc. Tissue reconfiguration
US6835200B2 (en) * 1999-06-22 2004-12-28 Ndo Surgical. Inc. Method and devices for tissue reconfiguration
US6663639B1 (en) * 1999-06-22 2003-12-16 Ndo Surgical, Inc. Methods and devices for tissue reconfiguration
US8287554B2 (en) * 1999-06-22 2012-10-16 Ethicon Endo-Surgery, Inc. Method and devices for tissue reconfiguration
US7846180B2 (en) 1999-06-22 2010-12-07 Ethicon Endo-Surgery, Inc. Tissue fixation devices and methods of fixing tissue
EP1149583A3 (de) * 2000-04-13 2001-11-14 Pfizer Products Inc. Kombinationen bestehend aus Antagonisten des Corticotropin freisetzenden Faktors und Stoffen, die die Wachstumshormonsekretion fördern
ES2333097T3 (es) * 2000-05-31 2010-02-17 Raqualia Pharma Inc Uso de secretagogos de la hormona de crecimiento para estimular la motilidad gastrointestinal.
EP1312363A1 (de) * 2001-09-28 2003-05-21 Pfizer Products Inc. Behandlungsverfahren und kits bestehend aus Wachstumshormonsekretionsförderern
US7491695B2 (en) 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
USRE42624E1 (en) 2003-06-18 2011-08-16 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
USRE42013E1 (en) 2003-06-18 2010-12-28 Tranzyme Pharma Inc. Macrocyclic modulators of the ghrelin receptor
US8921521B2 (en) 2003-06-18 2014-12-30 Ocera Therapeutics, Inc. Macrocyclic modulators of the Ghrelin receptor
ES2338789T3 (es) 2003-06-18 2010-05-12 Tranzyme Pharma Inc. Antagonistas macrociclicos del receptor de motilina.
US20090198050A1 (en) * 2003-06-18 2009-08-06 Tranzyme Pharma Inc. Macrocyclic Modulators of the Ghrelin Receptor
EP1641494A1 (de) * 2003-06-25 2006-04-05 F. Hoffmann-La Roche Ag Tritiierter wachstumshormon-sekretionförderer mk-0677
EP1648922B9 (de) * 2003-07-31 2013-04-03 Tranzyme Pharma Inc. Räumlich definierte makrocyclische verbindungen, die sich für die entdeckung von arzneimittel eignen
WO2005021026A2 (en) * 2003-08-29 2005-03-10 Amylin Pharmaceuticals, Inc. Methods for treating or ameliorating ghrelin-associated diseases and disorders
IL158658A0 (en) * 2003-10-29 2004-05-12 Moshe Schwarzberg Prokinetic drugs assistance to small intestine imaging
KR20070010151A (ko) * 2004-03-30 2007-01-22 사파이어 세라퓨틱스, 인크. 성장 호르몬 분비촉진제를 이용하여 ｃ-반응성 단백질을감소시키는 방법
US20070141156A1 (en) * 2005-12-21 2007-06-21 Uri Herzberg Compositions and methods for preventing or reducing postoperative ileus and gastric stasis
US8377906B2 (en) * 2004-06-04 2013-02-19 Ethicon, Inc. Compositions and methods for preventing or reducing postoperative ileus and gastric stasis
US8129359B2 (en) 2004-06-04 2012-03-06 Ethicon, Inc. Composition and method for treating post-surgical pain
PE20060574A1 (es) 2004-07-28 2006-06-24 Glaxo Group Ltd Derivados de arilpiperazina sulfonamida como agonistas de los receptores de secretagogos de la hormona del crecimiento (ghs)
US8039456B2 (en) 2004-08-12 2011-10-18 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using ipamorelin
EP1789067B8 (de) * 2004-08-12 2012-08-15 Helsinn Healthcare S.A. Verwendung von Wachstumshormon-sekretagoga zur Stimulierung der Motilität des gastrointestinalen Systems
CA2576915A1 (en) * 2004-08-18 2006-03-02 Elixir Pharmaceuticals, Inc. Growth-hormone secretagogues
US20090275648A1 (en) * 2005-06-13 2009-11-05 Fraser Graeme L Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
EP1919492B1 (de) * 2005-07-22 2013-03-06 Ipsen Pharma Wachstumshormonsekretagoga
RU2566708C2 (ru) * 2005-09-29 2015-10-27 Ипсен Фарма С.А.С. Композиции и способы стимуляции двигательной функции желудочно-кишечного тракта
US7576606B2 (en) * 2007-07-25 2009-08-18 D2Audio Corporation Digital PWM amplifier having a low delay corrector
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
PE20080176A1 (es) 2006-03-31 2008-04-25 Glaxo Group Ltd Compuestos de arilpiperazina sulfonamida como agonista de los receptores de secretagogos de la hormona de crecimiento (ghs)
US8088733B2 (en) 2006-07-06 2012-01-03 Tranzyme Pharma Inc. Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders
WO2008095063A1 (en) 2007-01-31 2008-08-07 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
ES2604943T3 (es) 2007-02-09 2017-03-10 Ocera Therapeutics, Inc. Moduladores macrocíclicos del receptor de la grelina y procedimientos de uso de los mismos
MX2009008561A (es) * 2007-02-13 2010-01-15 Helsinn Therapeutics Us Inc Metodo para tratar trastornos proliferativos celulares utilizando secretagogos.
US20080234703A1 (en) * 2007-03-23 2008-09-25 Ethicon Endo-Surgery, Inc. Tissue approximation system
US8852216B2 (en) 2007-03-23 2014-10-07 Ethicon Endo-Surgery, Inc. Tissue approximation methods
ES2430067T3 (es) 2007-03-28 2013-11-18 President And Fellows Of Harvard College Polipéptidos cosidos
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
US7728658B2 (en) * 2007-07-25 2010-06-01 D2Audio Corporation Low-noise, low-distortion digital PWM amplifier
PE20091102A1 (es) 2007-12-17 2009-07-25 Janssen Pharmaceutica Nv Moduladores imidazolo-, oxazolo-, y tiazolopirimidina del trpv1
CN101951937A (zh) * 2007-12-21 2011-01-19 赫尔辛医疗股份公司 使用伊帕瑞林刺激胃肠系统动力的方法
EP2334683B1 (de) * 2008-08-29 2017-03-22 MSD Italia S.r.l. Gesättigte bicyclische heterocyclische derivate als smo-antagonisten
KR100991032B1 (ko) * 2008-12-08 2010-10-29 삼일제약주식회사 위장관 운동 조절용 약학 조성물
CA2789750C (en) * 2010-02-26 2018-03-06 Raqualia Pharma Inc. Ghrelin receptor agonist for treatment of cachexia
DK2603600T3 (da) 2010-08-13 2019-03-04 Aileron Therapeutics Inc Peptidomimetiske makrocyklusser
US8546416B2 (en) * 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
CA2852468A1 (en) 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
SG10201606775YA (en) 2012-02-15 2016-10-28 Aileron Therapeutics Inc Peptidomimetic macrocycles
EP3524260B1 (de) 2012-09-27 2023-09-13 Elanco Animal Health Incorporated Pharmazeutische zusammensetzungen zur behandlung von appetitlosigkeit
CA2887285A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
JP2017533889A (ja) 2014-09-24 2017-11-16 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその使用
JP2018516844A (ja) 2015-03-20 2018-06-28 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその使用
JP6299683B2 (ja) 2015-06-25 2018-03-28 トヨタ自動車株式会社 燃料電池システム
EP3939590B1 (de) * 2015-09-21 2023-11-29 Lumos Pharma, Inc. Detektion und behandlung von wachstumshormonmangel

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4962115A (en) 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
EP0398961B1 (de) 1988-01-28 1994-11-02 Polygen Holding Corporation Polypeptidverbindungen mit wachstumshormonfreisetzender aktivität
EP0400051B1 (de) 1988-01-28 1995-05-10 Polygen Holding Corporation Polypeptide mit hormonwachstumsbefreiender wirkung
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
AU676525B2 (en) 1992-11-06 1997-03-13 Merck & Co., Inc. Substituted dipeptide analogs promote release of growth hormone
US5726319A (en) 1992-11-06 1998-03-10 Merck & Co., Inc. Biphenyl substituted dipeptide analogs promote release of growth hormone
HUT72076A (en) 1992-12-11 1996-03-28 Merck & Co Inc Process for preparing spiro piperidines and homologs which promote release of growth hormone and pharmaceutical compositions containing them
US5578593A (en) 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
AU8083694A (en) 1993-10-19 1995-05-08 Merck & Co., Inc. Combination of bisphosphonates and growth hormone secretagogues
US5492916A (en) 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5494919A (en) 1993-11-09 1996-02-27 Merck & Co., Inc. 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
WO1995013069A1 (en) 1993-11-09 1995-05-18 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
JPH09505601A (ja) 1993-11-24 1997-06-03 メルク エンド カンパニー インコーポレーテッド インドリル基含有化合物類および成長ホルモン放出を促進するためのそれらの使用
US5721251A (en) 1993-12-10 1998-02-24 Merck & Co., Inc. Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
AU683121B2 (en) 1993-12-23 1997-10-30 Novo Nordisk A/S Compounds with growth hormone releasing properties
US5721250A (en) 1993-12-23 1998-02-24 Merck & Co. Inc. Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
DE69426206T2 (de) 1993-12-23 2001-05-17 Novo Nordisk A/S, Bagsvaerd Verbindungen mit wachstumshormonfreisetzenden eigenschaften
WO1995034311A1 (en) 1994-06-13 1995-12-21 Merck & Co., Inc. Piperazine compounds promote release of growth hormone
AU3128195A (en) 1994-07-20 1996-02-16 Merck & Co., Inc. Piperidines and hexahydro-1h-azepines spiro substituted at the 4-position promote release of growth hormone
US5798337A (en) 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
WO1996022996A1 (en) 1995-01-25 1996-08-01 Nippon Chemiphar Co., Ltd. Dihydrophenazine derivatives
WO1996022997A1 (en) 1995-01-27 1996-08-01 Novo Nordisk A/S Compounds with growth hormone releasing properties
WO1996024587A1 (en) 1995-02-09 1996-08-15 Novo Nordisk A/S Compounds with growth hormone releasing properties
AU4534596A (en) 1995-02-09 1996-08-27 Novo Nordisk A/S Compounds with growth hormone releasing properties
US5559128A (en) 1995-04-18 1996-09-24 Merck & Co., Inc. 3-substituted piperidines promote release of growth hormone
WO1996033189A1 (en) 1995-04-19 1996-10-24 Merck & Co., Inc. Process for the preparation of spiroindolines
WO1996035713A1 (en) 1995-05-08 1996-11-14 Pfizer, Inc. Dipeptides which promote release of growth hormone
FI974368A7 (fi) 1995-05-29 1997-11-28 Pfizer Kasvuhormonin vapautumista edistäviä dipeptidejä
KR19990028303A (ko) 1995-06-22 1999-04-15 한센 핀 베네드, 안네 제헤르 성장호르몬 방출 특성을 가지는 화합물
CA2203428A1 (en) 1995-08-21 1997-02-27 Philip Arthur Hipskind 2-acylaminopropanamides as growth hormone secretagogues
ZA966891B (en) 1995-08-21 1998-02-16 Lilly Co Eli 2-acylaminopropanamines as growth hormone secretagogues.
AU7169696A (en) 1995-09-26 1997-04-17 Merck & Co., Inc. 3-spirolactam, 3-spiroamino, 3-spirolactone and 3-spirobenzopyran piperidines and pyrrolidines promote release of growth hormone
CZ128298A3 (cs) 1995-10-27 1998-07-15 Merck And Co., Inc. Způsob výroby N-/1(R)-/(1,2-dihydro-1-methansulfonylspiro/3H-indol-3,4´-piperdin/-1´-yl)karbonyl/-2-(fenylmethyloxy)-ethyl/-2-amino-2-methylpropanamidu
ATE279440T1 (de) 1995-12-13 2004-10-15 Merck & Co Inc Wachstumshormonsekretionsförderer rezeptorfamilie
JP3798024B2 (ja) 1995-12-13 2006-07-19 メルク エンド カンパニー インコーポレーテッド 成長ホルモン分泌促進物質レセプターアッセイ
IT1277113B1 (it) 1995-12-20 1997-11-04 Romano Deghenghi Composti oligopeptidici contenenti d-2-alchiltriptofano in grado di promuovere la liberazione dell'ormone della crescita
WO1997022367A1 (en) 1995-12-20 1997-06-26 Merck & Co., Inc. Radiolabeled growth hormone secretagogue
PL327227A1 (en) 1995-12-22 1998-12-07 Novo Nordisk As Compounds exhibiting growth hormone liberating properties
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
WO1997034604A1 (en) 1996-03-21 1997-09-25 Merck & Co., Inc. 4-spiroindoline piperidines promote release of growth hormone
WO1997036873A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
SE9601397D0 (sv) 1996-04-12 1996-04-12 Pharmacia Ab Use of growth hormone
WO1997040071A1 (en) 1996-04-19 1997-10-30 Novo Nordisk A/S Compounds with growth hormone releasing properties
US5919777A (en) 1996-04-24 1999-07-06 Novo Nordisk A/S Compounds with growth hormone releasing properties
ATE231131T1 (de) 1996-04-24 2003-02-15 Novo Nordisk As Verbindungen mit wachtumshormon freisetzenden eigenschaften
AU2931997A (en) 1996-05-07 1997-11-26 Merck & Co., Inc. Treatment of mood disorders with a growth hormone secretagogue
JP2001525793A (ja) 1996-05-14 2001-12-11 ノボ ノルディスク アクティーゼルスカブ ソマトスタチンの作動因子及び拮抗因子
US6071926A (en) 1996-05-22 2000-06-06 Arch Development Corporation Sleep quality improvement using a growth hormone secretagogue
IL126983A0 (en) 1996-05-31 1999-09-22 Novo Nordisk As Growth hormone components and bone anti-resorptive agent in cyclic (coherence) treatment of osteoporosis
ATE304528T1 (de) 1996-07-22 2005-09-15 Novo Nordisk As Verbindungen mit wachstumshormon-freisetzenden eigenschaften
AU4342097A (en) 1996-09-13 1998-04-02 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
WO1998046569A1 (fr) 1997-04-11 1998-10-22 Sumitomo Pharmaceuticals Co., Ltd. Derives de benzene
WO1998051687A1 (en) 1997-05-14 1998-11-19 Fujisawa Pharmaceutical Co., Ltd. Piperidino derivatives which promote growth hormone release
JP4116097B2 (ja) 1997-06-20 2008-07-09 ノボ ノルディスク アクティーゼルスカブ 成長ホルモン放出特性をもつ化合物
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
ATE356139T1 (de) * 1997-06-25 2007-03-15 Pfizer Dipeptidderivate zur förderung der sekretion von wachstumshormon
UA53716C2 (uk) * 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
ZA987383B (en) 1997-08-19 2000-02-17 Lilly Co Eli Treatment of congestive heart failure with growth hormone secretagogues.
KR100683445B1 (ko) 1997-08-22 2007-02-20 가켄 세야쿠 가부시키가이샤 신규한 아미드 유도체
US6211174B1 (en) * 1997-10-31 2001-04-03 Merck & Co., Inc. Naphtho-fused lactams promote release of growth hormone
US6358951B1 (en) * 1998-08-21 2002-03-19 Pfizer Inc. Growth hormone secretagogues
US6194578B1 (en) * 1998-11-20 2001-02-27 Pfizer Inc. Dipeptide derivatives
JP2003503055A (ja) * 1999-06-30 2003-01-28 ザイモジェネティクス，インコーポレイティド Ｓｇｉｐペプチド
WO2001091752A1 (en) * 2000-05-30 2001-12-06 Merck & Co., Inc. Melanocortin receptor agonists
ES2333097T3 (es) * 2000-05-31 2010-02-17 Raqualia Pharma Inc Uso de secretagogos de la hormona de crecimiento para estimular la motilidad gastrointestinal.

Also Published As

Publication number Publication date
JP3842987B2 (ja) 2006-11-08
JP2006265270A (ja) 2006-10-05
CA2349142A1 (en) 2001-11-30
JP2015127344A (ja) 2015-07-09
CA2349142C (en) 2005-07-12
US20020042419A1 (en) 2002-04-11
ES2333097T3 (es) 2010-02-17
US6548501B2 (en) 2003-04-15
AU4811401A (en) 2001-12-06
EP1159964A2 (de) 2001-12-05
ZA200104396B (en) 2002-11-29
JP2013139482A (ja) 2013-07-18
IL143388A0 (en) 2002-04-21
HU0102272D0 (en) 2001-08-28
EP1159964A3 (de) 2003-10-01
MY134190A (en) 2007-11-30
ATE446758T1 (de) 2009-11-15
EP1159964B1 (de) 2009-10-28
KR20010109139A (ko) 2001-12-08
US20030225096A1 (en) 2003-12-04
HUP0102272A3 (en) 2003-09-29
US6852722B2 (en) 2005-02-08
HUP0102272A2 (hu) 2002-02-28
NZ512072A (en) 2002-10-25
JP2002012556A (ja) 2002-01-15

Similar Documents

Publication Publication Date Title
DE60140285D1 (de) Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts
MXPA04005906A (es) Cis-2,4,5-trifenil-.imidazolinas y uso de la misma para tratamiento de tumores.
AU2134402A (en) Antiviral agents
TNSN04165A1 (en) Substituted hydroxyethylamines
IL154536A0 (en) Immunoregulatory compounds and derivatives and methods of treating diseases therewith
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
WO2004056365A3 (en) Derivatives of aryl-quinazoline/aryl-2amino-phenyl methanone which promote the release of parathyroid hormone
EP1175900A3 (de) Verwendung von Sekretionsfördermittel für Wachstumshormone zu Verbesserung des funktionellen Gesundheitsstatus
EP1184035A3 (de) Verwendung von Sekretionsfördermitteln für Wachstumshormone zu Behandlung des physischen Leistungsabbaus
PL377478A1 (pl) Cykloalkenowe kwasy dikarboksylowe jako środki przeciwzapalne, immunomodulujące oraz antyproliferacyjne
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
MXPA03011626A (es) Derivados de quinazolina que promueven la liberacion de hormona paratiroides.
IL150817A0 (en) Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases
WO2002058680A3 (en) Use of bicylic amino acids for preventing and treating visceral pain and gastrointestinal disorders
EP1181933A3 (de) Verwendung von wachstumshormonsekretion-fördernden mitteln zur appetit erholung
ATE292110T1 (de) Herstellungsverfahren von arylethanolaminderivate zur behandlung von diabetes und fettleibigkeit
EP1192943A3 (de) Verwendung von Sekretionsfördermitteln für Wachstumshormone in Verbindung mit Körpertraining
IL163025A (en) Prucalopride - n - oxides, their preparation and pharmaceutical compositions comprising them
TW200509917A (en) Use of growth hormone secretagogues for treatment of fibromyalgia
DE602004030265D1 (de) Behandlung von gastrointestinalen stromatumoren mit imatinib und midostaurin
DE60022047D1 (de) Antivirale therapie
IL143873A0 (en) Dry skin remedies
DE60104288D1 (de) Antivirale therapie
RU2000122595A (ru) Лекарственное средство для лечения пиелонефрита
TH51768A (th) สารประกอบคาร์บาฟีเนม การใช้ของสารดังกล่าว และสารประกอบตัวกลางสำหรับสารดังกล่าว

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: RAQUALIA PHARMA INC., AICHI-KEN, JP

8364 No opposition during term of opposition